DIAGENIC

for early disease detection

3rd Quarter 2012

Strengthened management and Board. A strategic redirection towards focused product development and commercialization in Alzheimer's Disease

Paul de Potocki, CEO
Magnus Sjögren, CMO
Ruben Ekbråten, CFO



Disclaimer

This document (the "Presentation") has been prepared by DiaGenic ASA (the "Company") exclusively for information purposes. Neither this Presentation nor any copy of it nor the information contained herein is being issued, and nor may this Presentation nor any copy of it nor the information contained herein be distributed directly or indirectly to or into, any jurisdiction in which such distribution would be unlawful or not appropriate. Recipients of the Presentation shall not reproduce, redistribute or pass on, in whole or in part, the Presentation or any of its content to any other person. The Presentation does not constitute, and should not be construed as, an offer to sell or a solicitation of an offer to buy any securities of the Company in any jurisdiction.

This Presentation contains certain forward-looking statements relating to the business, financial performance and results of the Company and/or the industry in which it operates. Forward-looking statements concern future circumstances and results and other statements that are not historical facts, and are sometimes identified by the words "believes", expects", "predicts", "intends", "projects", "plans", "estimates", "aims", "foresees", "anticipates", "targets", and similar expressions. The forward-looking statements contained in this Presentation, including assumptions, opinions and views of the Company or cited from third party sources, are solely opinions and forecasts which are subject to risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements that are expressed or implied by statements and information in the Presentation, including, among others, risks or uncertainties associated with the Company's business, segments, development, growth management, financing, market acceptance and relations with customers, and, more generally, general economic and business conditions, changes in domestic and foreign laws and regulations, taxes, changes in competition and pricing environments, and fluctuations in currency exchange rates and interest rates. None of the Company or any of its subsidiaries or any such person's directors, employees or advisors provide any assurance that the assumptions underlying forward-looking statements expressed in this Presentation are free from errors nor does any of them accept any responsibility for the future accuracy of such forward-looking statements.

The information contained in this Presentation has not been independently verified. No representation or warranty (express or implied) is made as to the accuracy or completeness of any information contained herein, and it should not be relied upon as such. None of the Company or its subsidiaries or any such person's directors, employees or advisors shall have any liability whatsoever arising directly or indirectly from the use of this Presentation. By reading the Presentation, or attending any oral presentation held in relation thereto, you acknowledge that you will be solely responsible for your own assessment of the Company, the market and the market position of the Company and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of the Company's business. The content of this Presentation are not to be construed as legal, business, investment or tax advice. Each recipient should consult with its own professional advisors for any such matters and advice.

No action has been taken to allow the distribution of this Presentation in any jurisdictions other than Norway. The Presentation has not been reviewed or registered with, or approved by, any public authority, stock exchange or regulated market. The distribution of this Presentation, as well as any subscription, purchase, sale or transfer of securities issued by the Company, may be restricted by law in certain jurisdictions, and persons into whose possession this Presentation comes are required by the Company to inform themselves about and comply with any such restrictions. Any failure to comply with such restrictions may constitute a violation of the laws of any such jurisdiction. None of the Company or its subsidiary undertakings or any such person's directors, employees or advisors shall have any responsibility for any such violations.

THIS PRESENTATION AND THE INFORMATION CONTAINED HEREIN DO NOT CONSTITUTE AN OFFER OF SECURITIES FOR SALE IN THE UNITED STATES AND ARE NOT FOR PUBLICATION OR DISTRIBUTION TO U.S. PERSONS (WITHIN THE MEANING OF REGULATION S UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT")). THE SECURITIES OF THE COMPANY HAVE NOT AND WILL NOT BE REGISTERED UNDER THE SECURITIES ACT, AND MAY NOT BE OFFERED OR SOLD WITHIN THE UNITED STATES OR TO U.S. PERSONS, EXCEPT PURSUANT TO AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT.

IN RELATION TO THE UNITED KINGDOM, THE PRESENTATION IS STRICTLY CONFIDENTIAL AND IS ONLY DIRECTED AT PERSONS WHO FALL WITHIN THE MEANING OF ARTICLE 19 (INVESTMENT PROFESSIONALS) AND 49 (HIGH NET WORTH COMPANIES, UNINCORPORATED ASSOCIATIONS, ETC.) OF THE FINANCIAL SERVICES AND MARKETS ACT 2000 (FINANCIAL PROMOTION) ORDER 2005 OR WHO ARE PERSONS TO WHOM THE PRESENTATION MAY OTHERWISE LAWFULLY BE DISTRIBUTED.

There may have been changes in matters which affect the Company subsequent to the date of this Presentation. Neither the issue nor delivery of this Presentation shall under any circumstance create any implication that the information contained herein is correct as of any time subsequent to the date hereof or that the affairs of the Company have not since changed, and the Company does not intend, and does not assume any obligation, except as required by law, to update or correct any information included in this Presentation.

This Presentation is subject to Norwegian law, and any dispute arising in respect of this Presentation is subject to the exclusive jurisdiction of the Norwegian courts.

Agenda

- Strategic focus
- Product development
- Financials
- Outlook and Summary

Value Creation

- Proprietary and validated technology
- Products to market
- Address unmet medical needs

Alzheimer's Disease (AD)

- Around 36 million people worldwide are living with dementia, with numbers doubling every twenty years
- An estimated 5.4 million Americans have AD, reaching 11-16 million in 2050
- Sixth leading cause of death
- Direct costs in the U.S. expected to be $200b in 2012, including $140b in costs to Medicare and Medicaid



- Without effective actions, the costs of AD in the U.S. in 2050 are estimated to total $1.1 trillion. Costs to Medicare and Medicaid will increase nearly 500%

Source: Alzheimer's Association 2012

A recent shift in focus – Earlier stage AD





Diagnostic Alternatives

- Patient assessment and cognitive function

Brain PET imaging	CSF biomarker	Gene expression
		
▪ Accurate detection of brain amyloid ▪ Single AD related biological process (Aβ) ▪ 20-30% false positives ▪ Limited access ▪ Expensive and time consuming	▪ Utility in AD research ▪ Includes two AD related biological processes (Aβ, Tau) ▪ >30% false positives ▪ Invasive procedure ▪ Lack of standardization	▪ Patient friendly, less invasive and fast ▪ Includes all known AD related biological processes ▪ Less expensive ▪ Requires regulatory clearances

Gene expression and AD pathology

- Amyloid-β
- Tau/Microtubules
- Neuron development
- Brain function
- Mitochondria
- Calcium regulation
- Oxidative stress
- Inflammation

IVD products based on 20 - 96 gene sets that accurately detect AD and AD-MCI

- ADtect® and MCItect® assays cover a wide range of known pathways associated with AD pathology, such as Amyloid-beta, pTau, neuro-degeneration and mitochondrial processing

Significant drug development investments



- The Alzheimer's disease drug market is worth $5.8bn in 2011, forecasted to grow to $14.5bn - 20bn by 2020
- New and expensive drug therapies expected to increase need and value of early diagnosis
- Pharma is increasingly targeting or re-targeting early stage AD

Important unmet needs in AD treatment paradigm shift

A patient friendly, minimally invasive and cost effective tool with competitive diagnostic accuracy that covers multiple pathways associated with AD, to help:

- Detect Alzheimer's Disease at early stage
- Differentiate MCI patients with and without AD
- Predict progression of MCI to AD
- Select patients eligible for brain PET scanning
- Follow disease progression

Strategic Focus Going Forward

- Alzheimer's Disease
- Product development and regulatory clearances in major markets
- Additional third party collaborations
- Position technology and company for strategic partnership and value creation

Agenda

- Strategic focus
- Product development
- Financials
- Outlook and Summary

Technology and products

Sample Collection PAXgene™ tubes



Total RNA Extraction PAXgene™ kit

RNA Quality Check



Prepare cDNA

Load MFC® with samples



Real-Time RT-PCR Viia7

Data analysis



Data for Bioinformatic analyses

PLS-R

ANN

= *DiaGenic developments*

Product pipeline for Alzheimer's Disease

MCItect®

- To detect patients with amnestic MCI who will progress to AD within two years
- Second generation MCItect® in validation, with optimized gene set and test accuracy of 81%

ADtect®

- To aid in the diagnosis of mild to moderate AD
- Second generation ADtect® in final developed, with fewer genes and improved test accuracy of 81%

AMYLOtect™

- IVD test to detect patients with brain amyloid that correlates with brain PET imaging. Studied in GE Healthcare collaboration

Regulatory Clearances



- Regulatory clearances are a prerequisite for the commercial development of products
- CE-marking in Europe planned for H1 2013
- Pre-IDE meeting with the FDA and pivotal U.S. clinical trials in active preparations

Recent collaboration agreements providing access to patient data

- Contract with Harvard Medical School to provide access to U.S. biomaterial and clinical data to enable validation of MCItect® in American patients with MCI. Studies planned to commence in the first quarter of 2013

- Agreement with European group, focused on MCI and AD, regarding access to patient data and samples. This will enable a major separate EU validation of MCItect® planned for 1Q 2013

Progression GEHC collaboration

- The collaborative study with GE Healthcare aiming at identifying a gene signature that identifies the presence of amyloid in the brain is progressing according to plan

  As per the 17th of October, 25 patients have been included in the study which aims to include 150 patients. A first read-out is preliminary planned for mid-2013

Further validation of DiaGenic technology – familial LRRK2 Parkinson disease

- Study 1 – Pilot study in Parkinson disease (PD) found gene signature that discriminated PD from controls with 88% accuracy



- Study 2 - Methodological validation study, collaboration Prof. Jan Aasly at St. Olavs Hospital, Trondheim, Norway
  - LRRK2 risk gene (mutation) for PD
  - 12 LRRK2-PD patients and 49 healthy LRRK2 mutation carriers



Objectives for additional collaborative partnerships

- It is likely that DiaGenic will enter into additional non-exclusive partnerships and collaborative development deals related to Alzheimer's Disease with industry partners
- Collaborative alliances with Pharma companies and other key stakeholders are of great strategic importance in the development and commercialization of DiaGenic's products going forward
- DiaGenic aims to maintain control of its IP and technology platform, and consequently we do not expect to create meaningful short term revenues from such collaborations

Agenda

- Strategic focus
- Product development
- Financials
- Outlook and Summary

Finance, Profit & Loss

P&L 3Q
(thousand NOK)

	3Q '12	3Q '11
Revenue	21	276
Grants	856	1,100
Operating Cost net of Grants	8,826	9,744
Operating loss	(8,805)	(9,468)
Net finance	197	493
Net income	(8,608)	(8,975)

Operating Cost
(thousand NOK)



	Q3 11	Q4 11	Q1 12	Q2 12	Q3 12
Cost of sales	133	245	320	110	14
Salaries and related	5 808	6 872	5 959	7 410	6 417
Depreciation and Write downs	261	222	224	225	221
Other operating cost	3 542	2 036	2 922	4 980	2 173

Finance,
Cash position and Financing



- Cash balance end of September 2012: NOK 28 million
- At current cost level and with no revenues, the estimated time to no cash is Q2 2013
- Assessment of the capital need and financing alternatives for strategy implementation is on-going and we are pleased to have DNB Markets supporting us in this work.

Agenda

- Strategic focus
- Product development
- Financials
- Outlook and Summary

Our goals for next 12 months include:

- Assessment of capital need and securing of financing for the implementation of a product development and disease focused strategy
- Patient recruitment for clinical trials in the U.S. to prepare for FDA approval of MCItect®
- CE marking of new ADtect® and MCItect® in Europe
- Entering into additional third party collaborative agreements related to Alzheimer's disease
- Presentation of results from the ongoing clinical study with GE Healthcare to identify gene signatures and an IVD test correlating with brain PET imaging

DiaGenic

DiaGenic ASA
Grenseveien 92, N-0663 Oslo, Norway
Tel +47 23 24 89 50
Mail: diagenic@diagenic.com
www.diagenic.com